Product Overview
MEFLUVAC™ H9+ND IMMUBOOST is an inactivated trivalent vaccine against LPAI (subtypes H9N2) and Newcastle Disease (GII and GVII) virus.
Popular Searches
MEFLUVAC™ H9+ND IMMUBOOST
Target Species
Chickens.
The importance of vaccination against LPAI and NDV infections
Low pathogenic avian influenza (LPAI) is a contagious, multi-organ systemic disease of poultry leading to high morbidity in poultry.1 The disease is caused by some H9 subtypes of type A influenza virus, family Orthomyxoviridae. 1 After mutation these LPAI viruses can become HPAI viruses, usually while they are circulating in poultry flocks.2
The Newcastle Disease Virus (NDV) genotypes I and II primarily represent vaccine strains, while the more virulent NDVs are clustered within genotypes III to X. Since the 1990s, genotype VIII expanded across Asia, South Africa, and parts of Europe; while genotype VII has been frequently reported in Europe, China, the Middle East, and South Africa.3,4,5,6
Vaccination is the primary control measure used to minimize losses.7
Product Description
Composition (Before Inactivation)
- Inactivated Low Pathogenic Avian Influenza H9N2 subtype, G1-lineage, [A/Chicken/Egypt/ FAO-S33/2021] ≥ 8.5 log10 EID50/dose.
- Inactivated Newcastle Disease Virus, Genotype II LaSota [ME/NDV3] ≥ 8.5 log10 EID50/dose.
- Inactivated recombinant Newcastle Disease Virus, Genotype VII [rg NDV1/ME.G7/2017] ≥ 8.5 log10 EID50/dose.
Indications
For early immunization of chickens against Low Pathogenic Avian Influenza H9N2 subtype and Newcastle Disease.
Vaccination Program
Birds can be vaccinated from the first day of age onwards, as per advice from your poultry veterinarian.
Immunity
- Onset of immunity: 3 weeks after the first vaccination.
- Duration of immunity: conditioned to the vaccination scheme established for the local epidemiological situation.
Withdrawal
Zero days.
Considerations
- For optimal booster effects, the birds should be primed with live NDV vaccines.
- Do not administer less than the recommended dosage.
- Allow the vaccine to reach room temperature (20-25°C) before use.
- The vaccine may occasionally separate into two layers on storage. This in no way affects its potency, but the vaccine should be shaken vigorously before and during use to ensure good emulsification.
Dosage
The vaccine dose (0.2 mL/bird) should be administered subcutaneously in the lower part of the neck or intramuscularly in the thigh or breast muscles.
Administration
Before use, the vaccine should be shaken well to ensure proper mixing. Sterile injection equipment should be used to avoid contamination. Do not use MEFLUVAC™ H9+ND IMMUBOOST if you notice critical irreversible separation of the emulsion.
- Subcutaneous injection: in the lower part of the neck. The needle should be inserted just under the skin in a direction away from the head and in a straight line with the neck.
- Intramuscular injection: in the breast muscles by inserting the needle with a 45° angle to avoid intraperitoneal injection.
Storage Precautions
- Store and transport refrigerated (+2°C to +8°C).
- Do not freeze.
- Store in a dry place protected from direct sunlight.
- Do not use this product after the expiry date.
- Shelf life after first opening the bottle: 3 hours.
Presentation
MEFLUVAC™ H9+ND IMMUBOOST is packed and presented in 500 mL (2500 doses) polyethylene terephthalate (PET) bottles.
Download the Product Information Sheet
MEFLUVAC™ H9+ND IMMUBOOST product infor...
References
1. Swayne DE, Suarez DL. Highly pathogenic avian influenza. Rev Sci Tech. 2000 Aug;19(2):463-82. doi: 10.20506/rst.19.2.1230. PMID: 10935274.
2. The Center for Food Security and Public Health, November 2015, Avian Influenza Fowl Plague, Grippe Aviaire.
3. A. Anis, M. AboElkhair, M. Ibrahim, Characterization of highly pathogenic avian influenza H5N8 virus from Egyptian domestic waterfowl in 2017, Avian Pathol. (2018), https://doi.org/10.1080/03079457.2018.1470606.
4. Abolnik C, Horner RF, Bisschop SP, Parker ME, Romito M, Viljoen GJ. A phylogenetic study of South African Newcastle disease virus strains isolated between 1990 and 2002 suggests epidemiological origins in the Far East. Arch Virol. 2004;149:603–619.
5. Herczeg J, Wehmann E, Bragg R, Travassos Dias PM, Hadjiev G, Werner O, Lomniczi B. Two novel genetic groups (VIIb and VIII) responsible for recent Newcastle disease outbreaks in Southern Africa, one (VIIb) of which reached Southern Europe. Arch Virol. 1999;144:2087–2099.
6. Ke GM, Liu HJ, Lin MY, Chen JH, Tsai SS, Chang PC. Molecular characterization of Newcastle disease viruses isolated from recent outbreaks in Taiwan. J Virol Methods. 2001;97:1–11.
7. Liu H, Wang Z, Wu Y, Zheng D, Sun C, Bi D, Zuo Y, Xu T. Molecular epidemiological analysis of Newcastle disease virus isolated in China in 2005. J Virol Methods. 2007;140:206–211.
Start Building Immunity against LPAI and NDV Infections
Fill out the form below to connect with Kemin's vaccine experts.
The content on this site is intended for informational purposes only and is not intended to be a substitute for professional veterinary advice. Although the information on this site is accessible worldwide, not all products or services are available to all persons or in all geographic locations or jurisdictions. Certain statements, product labeling and claims may differ by geography or as required by local governmental regulations.
